Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

P, Schmid; J, Cortes; R, Dent; L, Pusztai; H, McArthur; S, Kümmel; J, Bergh; C, Denkert; YH, Park; R, Hui; N, Harbeck; M, Takahashi; M, Untch; PA, Fasching; F, Cardoso; J, Andersen; D, Patt; M, Danso; M, Ferreira; MA, Mouret-Reynier; SA, Im; JH, Ahn; M, Gion; S, Baron-Hay; JF, Boileau; Y, Ding; K, Tryfonidis; G, Aktan; V, Karantza; J, O'Shaughnessy

doi:10.1056/nejmoa2112651

Public

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Shared by NobleBlocks on Feb 1, 2022 • 12:00 AM UTC

Authors:

Schmid P

Cortes J

Dent R

Abstract

<h4>Background</h4>The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!